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Abstract
Background: The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine
into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast
cancer (EBC) could improve efficacy, but this combination was not examined in this context so far.
Methods: Patients with stage II/IIIA EBC (four or more positive lymph nodes) received post-operative intensified
dose-dense sequential epirubicin (150 mg/m² every 2 weeks) and paclitaxel (225 mg/m² every 2 weeks) with
filgrastim and darbepoetin alfa, followed by capecitabine alone (dose levels 1 and 3) or with vinorelbine (dose
levels 2 and 4). Capecitabine was given on days 1-14 every 21 days at 1000 or 1250 mg/m
2 twice daily (dose levels
1/2 and 3/4, respectively). Vinorelbine 25 mg/m
2 was given on days 1 and 8 of each 21-day course (dose levels 2
and 4).
Results: Fifty-one patients were treated. There was one dose-limiting toxicity (DLT) at dose level 1. At dose level 2
(capecitabine and vinorelbine), five of 10 patients experienced DLTs. Therefore evaluation of vinorelbine was
abandoned and dose level 3 (capecitabine monotherapy) was expanded. Hand-foot syndrome and diarrhoea were
dose limiting with capecitabine 1250 mg/m
2 twice daily. At 35.2 months’ median follow-up, the estimated 3-year
relapse-free and overall survival rates were 82% and 91%, respectively.
Conclusions: Administration of capecitabine monotherapy after sequential dose-dense epirubicin and paclitaxel is
feasible in node-positive EBC, while the combination of capecitabine and vinorelbine as used here caused more
DLTs.
Trial registration: Current Controlled Trials ISRCTN38983527.
Background
Regimens containing both an anthracycline and a taxane
are standard of care for patients with high-risk early
breast cancer (EBC), such as those with four or more
positive nodes [1]. Dose-dense administration appears to
offer improved efficacy in node-positive disease [2,3]. In
the Intergroup/CALGB 9741 trial, dose-dense doxorubi-
cin, cyclophosphamide and paclitaxel significantly
improved disease-free survival (DFS) compared with
conventional dosing [2]. In a German Arbeitsge-
meinschaft Gynäkologische Onkologie (AGO) trial, adju-
vant dose-dense and dose-escalated sequential epirubicin
(150 mg/m
2), paclitaxel (225 mg/m
2) and cyclophospha-
mide (2500 mg/m
2) with granulocyte-colony stimulating
factor support (dose-escalated sequential epirubicin,
paclitaxel and cyclophosphamide [ddETC] regimen)
improved DFS and overall survival compared with con-
ventional therapy in patients with high-risk breast can-
cer. Although the ddETC regimen showed superior
efficacy, the importance of the 2500 mg/m²
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studies failed to demonstrate a benefit of cyclophospha-
mide dose escalation when given at 3-weekly intervals.
In addition, haematological toxicity in the ddETC regi-
men was most pronounced with cyclophosphamide [3].
Therefore, it is important to examine other compounds
as partners for dose-dense anthracycline and taxane
regimens, providing the rationale for this study.
Selection of appropriate chemotherapeutic agents in
this context should be based on activity, tolerability and
potential synergy. Capecitabine has demonstrated high
activity in a range of treatment situations for metastatic
breast cancer (MBC). Capecitabine monotherapy is effec-
tive after exposure to anthracyclines and taxanes [4], and
significantly improves overall survival versus classical
cyclophosphamide, methotrexate and 5-fluorouracil
(CMF) as first-line therapy [5]. The addition of capecita-
bine to docetaxel in anthracycline-pretreated MBC
improves overall survival [6]. However, in the adjuvant
setting, doxorubicin-cyclophosphamide (AC) or CMF
combination therapy were superior to capecitabine
monotherapy [7]. Thus, although the integration of
capecitabine into anthracycline and taxane combination
regimens appears feasible, the optimal schedule of cape-
citabine-containing regimens in the adjuvant and neoad-
juvant settings needs further investigation.
Another agent widely used in MBC is vinorelbine.
Published data from trials evaluating vinorelbine-
containing regimens suggest that replacing cyclopho-
sphamide with vinorelbine as monotherapy may offer
similar efficacy [8,9]. Although vinorelbine is often admi-
nistered as monotherapy, several phase II studies in MBC
have shown that the combination of vinorelbine and
capecitabine is active and well tolerated [10-12]. The
rationale for combining these two agents lies in their pre-
clinical synergy [13], single-agent activity and differing
safety profiles, with gastrointestinal effects and hand-foot
syndrome predominating with capecitabine, and myelo-
suppression characterising vinorelbine therapy.
The present study was originally initiated as a feasibil-
ity study for the randomised, phase III trial to follow the
ddETC study [3]. It was proposed that replacing high-
dose cyclophosphamide with agents that are not cross-
resistant to anthracyclines and taxanes might increase
efficacy while avoiding cyclophosphamide-related
toxicity.
Methods
Study objectives
The objective of the phase I part of the study was to
assess the feasibility and tolerability of capecitabine with
or without vinorelbine after intensified dose-dense
sequential epirubicin and paclitaxel as adjuvant therapy
in high-risk patients, and to identify the optimal dosing
regimen. In the phase II part of the study, the primary
objective was to determine 3-year DFS and 3-year over-
all survival. The study was conducted in accordance
with the Declaration of Helsinki. The study was
approved by the ethics committee State of Hessen,
Germany (approval number 38/2003).
Eligibility
Eligible patients were aged 18-65 years with histologi-
cally confirmed stage II/IIIA breast cancer with four or
more positive axillary lymph nodes. All patients had
undergone surgery (complete surgical resection [R0] of
breast tumour and axilla) before inclusion in the study.
Other key inclusion criteria included Eastern Coopera-
tive Oncology Group (ECOG) performance status 0 or
1, left ventricular ejection fraction within the normal
institutional range, and adequate haematological, renal
and hepatic function. Patients were excluded if they had
inflammatory breast cancer or had received neoadjuvant
endocrine therapy, chemotherapy or radiotherapy.
Patients with known dihydropyrimidine dehydrogenase
deficiency or creatinine clearance < 30 mL/min were
excluded. All patients provided written informed
consent.
Study treatment
Starting within 4 weeks after surgery, all patients
received three cycles of epirubicin 150 mg/m
2,d a y1
every 14 days, with filgrastim 5 μg/kg on days 3-10, fol-
lowed by three cycles of paclitaxel 225 mg/m
2,g i v e na s
a 3-hour infusion on day 1 every 14 days, with filgrastim
as above. Patients then received four cycles of capecita-
bine days 1-14 either alone (dose levels 1 and 3) or in
combination with vinorelbine at 25 mg/m² on days 1
and 8 of each 21-day cycle (dose levels 2 and 4). Dose
levels were defined as follows: level 1: capecitabine 1000
mg/m²; level 2: capecitabine 1000 mg/m² plus vinorel-
bine 25 mg/m² days 1 and 8; level 3: capecitabine 1250
mg/m²; level 4: capecitabine 1250 mg/m² plus vinorel-
bine 25 mg/m² days 1 and 8.
The starting doses were selected because these or
higher doses had demonstrated good tolerability in pre-
vious studies in the metastatic setting [11,12]. All
patients received darbepoetin alfa from day 1 of che-
motherapy until the end of radiotherapy (starting dose
of 300 μg weekly for 4 weeks, after this every 3 weeks).
Patients with hormone receptor-positive disease received
tamoxifen 20 mg/day for 5 years after completion of
chemotherapy.
Ten patients were to be enrolled to each dose level. If
fewer than three of 10 patients experienced dose-limiting
toxicity (DLT, defined as grade 4 febrile neutropenia,
g r a d e4d i a r r h o e ao rg r a d e3d iarrhoea lasting > 5 days,
grade 3/4 neurotoxicity, grade 3 hand-foot syndrome, or
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Page 2 of 8treatment-related death), patients were enrolled to the
next dose level. If three of 10 patients experienced a
DLT, an additional five patients were enrolled to that
dose level and if more than three experienced a DLT this
level was to be rejected. The different parts of the treat-
ment are outlined in Figure 1.
Results
Patient population
A total of 51 patients were enrolled in 10 centres
between October 2003 and July 2006, all of whom were
evaluable. Median age was 53 years (range 32-67) in the
overall population, although patients in the lower two
dose levels were typically slightly younger than those in
the upper two dose levels (Table 1).
Treatment exposure
All but two patients completed all planned cycles of
epirubicin and paclitaxel. One patient completed all
three cycles of epirubicin but discontinued after only
two cycles of paclitaxel because of deterioration of phy-
sical condition and breast infection. The second discon-
tinued after the first cycle of epirubicin because of
febrile neutropenia. One additional patient was with-
drawn before initiation of capecitabine therapy because
brain metastases were observed after completion of all
planned cycles of epirubicin and paclitaxel.
The mean delivered dose was very close to the
planned dose for both epirubicin and paclitaxel. The
planned dose of epirubicin or paclitaxel was reduced in
43 of 300 (14.3%) cycles, most frequently because of
treatment-related haematological adverse events (23
cycles, 8%). Of the 51 patients recruited (including the
three described above who received no study treatment),
72% received all four planned cycles of capecitabine and
14% received three cycles. Four cycles of vinorelbine
(day 1 and/or day 8) were given in 67% of the 15
patients accrued to vinorelbine-containing dose levels
and 20% received three cycles.
All patients received at least one dose of darbepoetin
alfa during the treatment with ET. The majority of
patients (71%) received darbepoetin alfa during capecita-
bine (with or without vinorelbine) therapy: 88% and 58%
in the two capecitabine monotherapy cohorts and 90%
and 75% in the two vinorelbine-treated cohorts.
Safety
As defined in the protocol, the safety analysis included
all patients who received at least one cycle of che-
motherapy. Forty-eight patients received at least one
dose of capecitabine (with vinorelbine at dose levels 2
and 4). A total of 176 cycles were administered: 27 to
eight patients at dose level 1, 37 to 10 patients at dose
l e v e l2 ,9 8t o2 6p a t i e n t sa td o s el e v e l3a n d1 4t of o u r
patients at dose level 4. At dose level 1, one patient
experienced grade 4 paraesthesia and grade 3 hand-foot
syndrome. At dose level 2 (capecitabine 1000 mg/m
2
plus vinorelbine 25 mg/m
2), five of the 10 patients
experienced DLTs (grade 3 hand-foot syndrome in two
patients, grade 4 diarrhoea in one patient, febrile neu-
tropenia in two patients [accompanied by grade 4 leuco-
penia in one of these patients]). The high incidence of
DLTs at dose level 2 led to discontinuation of dose level
4, but since there had been only one DLT at dose level
1 (capecitabine monotherapy), accrual continued to dose
level 3 (single-agent capecitabine 1250 mg/m
2 twice
daily). At this dose level, there were four patients with
grade 3 hand-foot syndrome, one with grade 4 diar-
rhoea, and two with febrile neutropenia (Table 2).
The most common adverse events were alopecia, nau-
sea, fatigue, stomatitis and hand-foot syndrome (39%)
(Table 2). The majority of adverse events were grade 1
or 2. The most common grade 3/4 adverse events were
hand-foot syndrome (14%), vomiting (12%), febrile
Tamoxifen 
Epirubicin 
150 mg/m2, 
day 1 q2w
Paclitaxel 
225 mg/m2, 
day 1 q2w
Capecitabine 1,000/1,250 mg/m2 bid, 
days 1–14 q21d
135791 1 1 3 1 6 1 9
20 mg/day 
for 5 years 
in hormone 
receptor-
positive
Radiotherapy Week
positive 
patients
Vinorelbine 25 mg/m2
days 1 and 8 q21d
Filgrastim 5 μg/kg, days 3–10 q2w
y q
Darbepoetin alfa
Figure 1 Different parts of the treatment schedule. Patients received dose-dense sequential epirubicin and paclitaxel, followed by
capecitabine alone (dose levels 1 and 3) or with vinorelbine (dose levels 2 and 4).
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Page 3 of 8neutropenia (12%), nausea (10%) and diarrhoea (8%). No
grade 3/4 anaemia was observed. Only three patients
required red blood cell transfusion; none required
thrombocyte transfusion. Median haemoglobin levels
were 11.9 g/dL (range 8.4-14.5) at cycle 1 and 13.5 g/dL
(range 10.3-14.8) at the end of chemotherapy. Four
thrombotic events were reported, two of them in axillary
veins related to implanted venous port systems.
The most common reasons for capecitabine or vinor-
elbine dose reduction or treatment delay were treat-
ment-related non-haematological toxicity in 23 cycles
(13%) and haematological toxicity in six cycles (3%). At
d o s el e v e l s2a n d4( v i n o r e l b ine-containing regimens),
11% and 7% of cycles, respectively, were delayed because
of haematological adverse events, compared with 0 and
1% of non-vinorelbine cycles at dose levels 1 and 3.
Non-haematological adverse events showed a less clear
pattern, leading to dose reduction or delay in 19%, 3%,
13%, and 27% of cycles at dose levels 1, 2, 3 and 4,
respectively.
Efficacy
Median duration of follow-up is 35.2 months. With this
follow-up, nine recurrences (18%) and four deaths (8%)
have been documented. The estimated 3-year relapse-
free survival rate is 82% (95% confidence interval [CI]:
0.71-0.93) (Figure 2), and estimated 3-year overall survi-
val rate is 91% (95% CI: 0.83-1.0).
Discussion
The findings of this study suggest that capecitabine
monotherapy after dose-dense sequential epirubicin and
paclitaxel is feasible, whereas the addition of vinorelbine
to capecitabine resulted in unacceptable toxicity as pre-
defined by the protocol. Consequently evaluation of the
capecitabine-vinorelbine combination after dose-dense
epirubicin plus paclitaxel was abandoned in this pilot
study.
This is only one of the capecitabine-containing regi-
mens being evaluated in the adjuvant situation. In a ran-
domised, neoadjuvant trial, the combination of docetaxel
Table 1 Baseline characteristics
Overall population
(n = 51)
Dose level 1
(n = 10)
Dose level 2
(n = 11)
Dose level 3
(n = 26)
Dose level 4
(n = 4)
Median age, years (range) 53 (32-67) 49 (37-64) 49 (32-64) 55 (35-67) 56 (49-56)
ECOG performance status (%)
0 8 0 8 08 28 82 5
1 2 0 2 01 81 27 5
Tumour stage (%)
1 2 5 4 01 82 32 5
2 6 7 6 08 26 27 5
3 6 0 0 12 0
4 2 0040
Nodal stage (%)
1 10 0 18 12 0
2 5 3 6 04 55 45 0
3 3 7 4 03 63 55 0
Involved lymph nodes
Median number 9 10 9 7.5 7.5
3-6* (%) 39 20 45 42 50
7-9 (%) 20 30 9 23 0
10-14 (%) 20 10 27 19 25
15-19 (%) 12 20 9 8 25
≥20 (%) 10 20 9 8 0
Hormone receptor status (%)
ER or PgR positive 76 80 64 77 100
ER and PgR negative 24 20 36 23 0
HER2 status (%)
Positive 33 40 27 27 75
Negative 63 60 64 69 25
Unknown 4 0 9 4 0
*One patient had only three involved nodes but was included in all analyses
ECOG, Eastern Cooperative Oncology Group, ER, oestrogen receptor, PgR, progesterone receptor
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pathologic complete response rate than doxorubicin
plus cyclophosphamide [14] and early results from the
randomised European Cooperative Trial in Operable
Breast Cancer II (ECTOII) trial demonstrated more
favourable efficacy with capecitabine-containing regi-
mens than those without capecitabine [15]. In contrast,
in the GeparQuattro study, von Minckwitz et al. were
unable to show additional benefit when capecitabine
was added to a highly effective neoadjuvant taxane- and
anthracycline-containing regimen [16].
In the adjuvant setting, results of a randomised,
phase III trial demonstrated favourable efficacy when
capecitabine was given in combination with docetaxel
followed by epirubicin, cyclophosphamide and capeci-
tabine (TX®CEX) versus docetaxel alone followed by
5-fluorouracil (5-FU), epirubicin and cyclophospha-
mide (T®CEF). The estimated 34% risk reduction in
relapse-free survival appears substantial [17]. In con-
trast, a study comparing adjuvant capecitabine mono-
therapy to either AC or CMF combination therapy in
older patients showed the latter regimens to be super-
ior [7]. These results allow no definitive conclusion
about the role of capecitabine in the adjuvant setting.
Currently, the impact of adding vinorelbine to capeci-
tabine after anthracycline and taxane exposure is not
clear. In the absence of randomised data in EBC, extra-
polation from the metastatic setting possibly provides
Table 2 Summary of most common ( > 20%) adverse events and grade 3/4 adverse events in > 5% of patients
Overall population (n = 51) Dose level 3 (recommended dose) (n = 26)
Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 1 Grade 2 Grade 3 Grade 4 Total
Alopecia 1 (2%) 38 (75%) 0 0 39 (76%) 0 24 (92%) 0 0 24 (92%)
Nausea 21 (41%) 9 (18%) 3 (6%) 2 (4%) 35 (69%) 16 (62%) 3 (12%) 1 (4%) 1 (4%) 21 (81%)
Fatigue 12 (24%) 17 (33%) 0 0 29 (57%) 8 (31%) 8 (31%) 0 0 16 (62%)
Stomatitis 18 (35%) 6 (12%) 2 (4%) 0 26 (51%) 8 (31%) 4 (15%) 2 (8%) 0 14 (54%)
Hand-foot syndrome 7 (14%) 6 (12%) 7 (14%) 0 20 (39%) 5 (19%) 4 (15%) 4 (15%) 0 13 (50%)
Nail disorder 7 (14%) 11 (22%) 0 1 (2%) 19 (37%) 4 (15%) 6 (23%) 0 0 10 (38%)
Constipation 14 (27%) 5 (10%) 0 0 19 (37%) 5 (19%) 3 (12%) 0 0 8 (31%)
Arthralgia 6 (12%) 9 (18%) 1 (2%) 0 1 (31%) 4 (15%) 3 (12%) 1 (4%) 0 8 (31%)
Bone pain 7 (14%) 5 (10%) 0 0 12 (24%) 5 (19%) 3 (12%) 0 0 8 (31%)
Paraesthesia 6 (12%) 4 (8%) 1 (2%) 1 (2%) 12 (24%) 3 (12%) 3 (12%) 0 0 6 (23%)
Diarrhoea 5 (10%) 3 (6%) 2 (4%) 2 (4%) 12 (24%) 1 (4%) 2 (8%) 1 (4%) 1 (4%) 5 (19%)
Headache 5 (10%) 4 (8%) 2 (4%) 0 11 (22%) 3 (12%) 0 1 (4%) 0 4 (15%)
Anorexia 6 (12%) 5 (10%) 0 0 11 (22%) 4 (15%) 1 (4%) 0 0 5 (19%)
Vomiting 7 (14%) 2 (4%) 4 (8%) 2 (4%) 15 (29%) 3 (12%) 0 2 (8%) 2 (8%) 7 (27%)
Febrile neutropenia 0 0 3 (6%) 3 (6%) 6 (12%) 0 0 2 (8%) 0 2 (8%)
Neutropenia 0 1 (2%) 1 (2%) 2 (4%) 4 (8%) 0 1 (4%) 1 (4%) 1 (4%) 3 (12%)
Impaired healing 0 0 1 (2%) 1 (2%) 2 (4%) 0 0 1 (4%) 1 (4%) 2 (8%)
Myalgia 6 (12%) 2 (4%) 0 0 8 (16%) 6 (23%) 1 (4%) 0 0 7 (27%)
Hypersensitivity 3 (6%) 2 (4%) 1 (2%) 0 6 (12%) 3 (12%) 2 (8%) 1 (4%) 0 6 (23%)
Figure 2 Kaplan-Meier estimation of relapse-free survival a) overall population; b) dose level 3.
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well tolerated and has shown substantial efficacy in
MBC. However, cross-trial comparison does not clearly
indicate that addition of vinorelbine to capecitabine
increases the efficacy in patients previously exposed to
anthracyclines and taxanes [11,18,19]. Therefore, with-
out randomised data in either the metastatic or adjuvant
setting, no firm conclusions can be drawn.
In the neoadjuvant GEPARTRIO trial, patients who
did not show a response after two cycles of docetaxel,
doxorubicin and cyclophosphamide (TAC) were rando-
mised to either four further cycles of TAC or four cycles
of capecitabine and vinorelbine. In contrast to our find-
ings, administration of vinorelbine and capecitabine
after TAC was feasible, resulting in similar efficacy but
better tolerability than continuing TAC [20]. However,
to our knowledge no other trials have tested the combi-
nation of capecitabine-vinorelbine as front-line therapy
in patients with EBC, and TAC was not dose dense and
escalated as in our study.
Compared with the AGO trial evaluating the ddETC
regimen, the capecitabine-containing regimens were well
tolerated. At both capecitabine doses, gastrointestinal
toxicities and hand-foot syndrome were among the most
frequently reported grade 3/4 non-haematological
adverse effects. However, there were fewer cyclopho-
sphamide-related toxicities, such as stomatitis, pain,
infection and skin toxicity. As expected, grade 3 hand-
foot syndrome and grade 4 diarrhoea were dose limiting,
occurring in four patients and one patient, respectively,
treated at the higher dose of 1250 mg/m
2 twice daily.
S i n c et h i st r i a lw a si n i t i a t e d ,ar a n d o m i s e d ,p h a s eI I I
trial of first-line capecitabine monotherapy versus classi-
cal CMF for MBC demonstrated that a dose of 1000
mg/m
2 twice daily is very active, resulting in a signifi-
cant survival benefit [5]. Moreover, retrospective ana-
lyses and non-randomised trials in MBC suggest that
this lower dose is associated with better tolerability
without compromising efficacy [21-23]. As a conse-
quence the lower dose is frequently used in clinical
practice. The evaluation of lower dose levels was not
planned because when the present study was designed,
it was assumed that dose levels 1 and 2 were feasible
and well tolerated in the metastatic situation, a hypoth-
esis confirmed by studies published after initiation of
our study [10-12].
For a population with a median of nine positive axil-
lary lymph nodes, the 82% 3-year relapse-free survival
rate after 35.2 months’ median follow-up is within the
range reported for dose-dense anthracycline-taxane-
cyclophosphamide regimens [2,3,24,25]. Long-term fol-
low-up is ongoing.
Darbepoetin alfa was effective in preventing grade 3/4
anaemia. However, since starting this phase I/II study,
the general consensus on the role of epoetin-containing
drugs in cancer patients has changed substantially and
current guidelines demand a more cautious use of these
compounds as in our study [26,27]. This is based on
some data suggesting poorer overall survival in non-
anaemic patients receiving epoetin compared with pla-
cebo [28] and increased risk of thromboembolism [29].
In the 2007 update of the St. Gallen guidelines for man-
agement of EBC [30] haematopoietic growth factors
were considered by most panel members to have a role
in patients with a clinical indication, although only a
minority supported their routine use. The current St.
Gallen statement of 2009 does not mention this topic.
However, analyses from the ddETC trial indicated that
epoetin administration enabled maintenance of a stable
median haemoglobin value and avoided the need for
blood transfusions, without any negative impact on
relapse-free and overall survival [3].
Conclusion
Taken together, our results show that after intensified
dose-dense epirubicin and paclitaxel, the combination of
capecitabine and vinorelbine appears unfeasible. These
results influenced the design of the recently completed
GAIN (German Adjuvant Intergroup Node-positive)
trial. Consequently, patients in GAIN were randomised
to either ddETC or an investigational epirubicin and
cyclophosphamide followed by capecitabine and pacli-
taxel (EC®XP) arm (four 14-day cycles of epirubicin
112.5 mg/m
2 plus cyclophosphamide 600 mg/m
2,f o l -
lowed by four 21-day cycles of capecitabine 1000 mg/m
2
twice daily administered on days 1-14 in combination
with weekly paclitaxel 67.5 mg/m
2 for 10 weeks). The
low relapse rate observed in the study described here
supports the concept of dose-dense therapy. In this con-
text, our results should help to optimise the design of
further clinical trials in high-risk breast cancer.
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